Medicare Agency Sees Role For Itself In Device Postmarket Surveillance
This article was originally published in The Pink Sheet Daily
The fiscal 2008 hospital inpatient proposed rule reveals CMS’s growing perception of itself as a public health agency, not just a payor, and in many ways blurs the line between FDA and CMS responsibilities.
You may also be interested in...
The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.
NIH and government agencies plan to submit plans to Congress next month describing ways to encourage the development of medical devices for children.
Do not be cavalier about this venue, drug/device lawyer warns.